Víctor Fanjul

Víctor Fanjul

Auto-generated profile, based on publicly available information

Víctor Fanjul

Centro Nacional de Investigaciones Cardiovasculares (CNIC). Madrid. Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2021 in European Journal of Neurology
Verified
Journal Article
Open access
PDF file
AGAlicia Gonzalez-Martinez
Alicia Gonzalez-Martinez
VFVíctor Fanjul
Víctor Fanjul
CRCarmen Ramos
Carmen Ramos
JBJorge Serrano Ballesteros
Jorge Serrano Ballesteros
MBMarta Bustamante
Marta Bustamante
AGAna Beatriz Gago-Veiga
Ana Beatriz Gago-Veiga
Background and purpose: Headache is an important manifestation during SARS‐CoV‐2 infection. In this study, the aim was to identify factors associated with headache in COVID‐19 and headache characteristics.Methods: This case–control study includes COVID‐19 hospitalized patients with pneumonia during March 2020. Controls comprise COVID‐19 patients without headache and the cases are COVID‐19 patients with headache. Demographic, clinical and laboratory data were obtained from the medical records. Headache characteristics were evaluated by semi‐structured telephonic interview after discharge.Results: Of a total of 379 COVID‐19 patients, 48 (13%) developed headache. Amongst these, 30 (62%) were men and the median age was 57.9 (47–73) years. Headache was associated with younger age, fewer comorbidities and reduced mortality, as well as with low levels of C‐reactive protein, mild acute respiratory distress syndrome and oropharyngeal symptoms. A logistic multiple regression model revealed that headache was directly associated with D‐dimer and creatinine levels, the use of high flow nasal cannula and arthromyalgia, whilst urea levels, beta‐lactamic treatment and hypertension were negatively associated with headache. COVID‐19‐associated headache characteristics were available for 23/48 (48%) patients. Headache was the onset symptom in 8/20 (40%) patients, of mild or moderate intensity in 17/20 (85%) patients, with oppressive characteristics in 17/18 (94%) and of holocranial 8/19 (42%) or temporal 7/19 (37%) localization.Conclusions: Our results show that headache is associated with a more benign SARS‐CoV‐2 infection. COVID‐19‐associated headache appears as an early symptom and as a novel headache with characteristics of headache attributed to systemic viral infection. Further research addressing the underlying mechanisms to confirm these findings is warranted.

30 November 2021 in Circulation
Verified
Journal Article
Open access
PDF file
ASAmanda Sánchez-López
Amanda Sánchez-López
CECarla Espinós-Estévez
Carla Espinós-Estévez
CGCristina González-Gómez
Cristina González-Gómez
PGPilar Gonzalo
Pilar Gonzalo
MAMaría J. Andrés-Manzano
María J. Andrés-Manzano
VAVicente Andrés
Vicente Andrés
Background: Hutchinson-Gilford progeria syndrome (HGPS) is a rare disorder characterized by premature aging and death mainly because of myocardial infarction, stroke, or heart failure. The disease is provoked by progerin, a variant of lamin A expressed in most differentiated cells. Patients look healthy at birth, and symptoms typically emerge in the first or second year of life. Assessing the reversibility of progerin-induced damage and the relative contribution of specific cell types is critical to determining the potential benefits of late treatment and to developing new therapies. Methods: We used CRISPR-Cas9 technology to generate Lmna HGPSrev/HGPSrev ( HGPSrev ) mice engineered to ubiquitously express progerin while lacking lamin A and allowing progerin suppression and lamin A restoration in a time- and cell type–specific manner on Cre recombinase activation. We characterized the phenotype of HGPSrev mice and crossed them with Cre transgenic lines to assess the effects of suppressing progerin and restoring lamin A ubiquitously at different disease stages as well as specifically in vascular smooth muscle cells and cardiomyocytes. Results: Like patients with HGPS, HGPSrev mice appear healthy at birth and progressively develop HGPS symptoms, including failure to thrive, lipodystrophy, vascular smooth muscle cell loss, vascular fibrosis, electrocardiographic anomalies, and precocious death (median lifespan of 15 months versus 26 months in wild-type controls, P <0.0001). Ubiquitous progerin suppression and lamin A restoration significantly extended lifespan when induced in 6-month-old mildly symptomatic mice and even in severely ill animals aged 13 months, although the benefit was much more pronounced on early intervention (84.5% lifespan extension in mildly symptomatic mice, P <0.0001, and 6.7% in severely ill mice, P <0.01). It is remarkable that major vascular alterations were prevented and lifespan normalized in HGPSrev mice when progerin suppression and lamin A restoration were restricted to vascular smooth muscle cells and cardiomyocytes. Conclusions: HGPSrev mice constitute a new experimental model for advancing knowledge of HGPS. Our findings suggest that it is never too late to treat HGPS, although benefit is much more pronounced when progerin is targeted in mice with mild symptoms. Despite the broad expression pattern of progerin and its deleterious effects in many organs, restricting its suppression to vascular smooth muscle cells and cardiomyocytes is sufficient to prevent vascular disease and normalize lifespan.

24 February 2021 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
Álvaro MacíasÁlvaro Macías
Álvaro Macías
JDJ Jaime Díaz-Larrosa
J Jaime Díaz-Larrosa
YBYaazan Blanco
Yaazan Blanco
VFVíctor Fanjul
Víctor Fanjul
CGCristina González-Gómez
Cristina González-Gómez
VAVicente Andrés
Vicente Andrés
Hutchinson–Gilford progeria syndrome (HGPS) is an ultrarare laminopathy caused by expression of progerin, a lamin A variant, also present at low levels in non-HGPS individuals. HGPS patients age and die prematurely, predominantly from cardiovascular complications. Progerin-induced cardiac repolarization defects have been described previously, although the underlying mechanisms are unknown. We conducted studies in heart tissue from progerin-expressing LmnaG609G/G609G (G609G) mice, including microscopy, intracellular calcium dynamics, patch-clamping, in vivo magnetic resonance imaging, and electrocardiography. G609G mouse cardiomyocytes showed tubulin-cytoskeleton disorganization, t-tubular system disruption, sarcomere shortening, altered excitation–contraction coupling, and reductions in ventricular thickening and cardiac index. G609G mice exhibited severe bradycardia, and significant alterations of atrio-ventricular conduction and repolarization. Most importantly, 50% of G609G mice had altered heart rate variability, and sinoatrial block, both significant signs of premature cardiac aging. G609G cardiomyocytes had electrophysiological alterations, which resulted in an elevated action potential plateau and early afterdepolarization bursting, reflecting slower sodium current inactivation and long Ca+2 transient duration, which may also help explain the mild QT prolongation in some HGPS patients. Chronic treatment with low-dose paclitaxel ameliorated structural and functional alterations in G609G hearts. Our results demonstrate that tubulin-cytoskeleton disorganization in progerin-expressing cardiomyocytes causes structural, cardiac conduction, and excitation–contraction coupling defects, all of which can be partially corrected by chronic treatment with low dose paclitaxel.

30 July 2020 in Aging Cell
Verified
Journal Article
Open access
PDF file
VFVíctor Fanjul
Víctor Fanjul
IJInmaculada Jorge
Inmaculada Jorge
ECEmilio Camafeita
Emilio Camafeita
Álvaro MacíasÁlvaro Macías
Álvaro Macías
CGCristina González‐Gómez
Cristina González‐Gómez
VAVicente Andrés
Vicente Andrés
Aging is the main risk factor for cardiovascular and metabolic diseases, which have become a global concern as the world population ages. These diseases and the aging process are exacerbated in Hutchinson–Gilford progeria syndrome (HGPS or progeria). Here, we evaluated the cardiometabolic disease in animal models of premature and normal aging with the aim of identifying alterations that are shared or specific to each condition. Despite differences in body composition and metabolic markers, prematurely and normally aging mice developed heart failure and similar cardiac electrical abnormalities. High‐throughput proteomics of the hearts of progeric and normally aged mice revealed altered protein oxidation and glycation, as well as dysregulated pathways regulating energy metabolism, proteostasis, gene expression, and cardiac muscle contraction. These results were corroborated in the hearts of progeric pigs, underscoring the translational potential of our findings, which could help in the design of strategies to prevent or slow age‐related cardiometabolic disease.

10 August 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Carlos Gonzalez-JuanateyCarlos Gonzalez-Juanatey
Carlos Gonzalez-Juanatey
MAManuel Anguita
Manuel Anguita
Vivencio BarriosVivencio Barrios
Vivencio Barrios
INIván J. Núñez-Gil
Iván J. Núñez-Gil
JDJuan Jose Gomez Doblas
Juan Jose Gomez Doblas
MTMiren Taberna
Miren Taberna
Patients with type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD) without myocardial infarction (MI) or stroke are at high risk for major cardiovascular events (MACEs). We aimed to provide real-world data on age-related clinical characteristics, treatment management, and incidence of major cardiovascular outcomes in T2DM-CAD patients in Spain from 2014 to 2018. We used EHRead® technology, which is based on natural language processing and machine learning, to extract unstructured clinical information from electronic health records (EHRs) from 12 hospitals. Of the 4072 included patients, 30.9% were younger than 65 years (66.3% male), 34.2% were aged 65–75 years (66.4% male), and 34.8% were older than 75 years (54.3% male). These older patients were more likely to have hypertension (OR 2.85), angina (OR 1.64), heart valve disease (OR 2.13), or peripheral vascular disease (OR 2.38) than those aged <65 years (p < 0.001 for all comparisons). In general, they were also more likely to receive pharmacological and interventional treatments. Moreover, these patients had a significantly higher risk of MACEs (HR 1.29; p = 0.003) and ischemic stroke (HR 2.39; p < 0.001). In summary, patients with T2DM-CAD in routine clinical practice tend to be older, have more comorbidities, are more heavily treated, and have a higher risk of developing MACE than is commonly assumed from clinical trial data.

11 October 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Carlos Gonzalez-JuanateyCarlos Gonzalez-Juanatey
Carlos Gonzalez-Juanatey
MAManuel Anguita
Manuel Anguita
Vivencio BarriosVivencio Barrios
Vivencio Barrios
INIván J. Núñez-Gil
Iván J. Núñez-Gil
JDJuan Jose Gomez Doblas
Juan Jose Gomez Doblas
SGSAVANA Research Group
SAVANA Research Group
Patients with Type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD) are at high risk of developing major adverse cardiovascular events (MACE). This is a multicenter, retrospective, and observational study performed in Spain aimed to characterize these patients in a real-world setting. Unstructured data from the Electronic Health Records were extracted by EHRead®, a technology based on Natural Language Processing and machine learning. The association between new MACE and the variables of interest were investigated by univariable and multivariable analyses. From a source population of 2,184,662 patients, we identified 4072 adults diagnosed with T2DM and CAD (62.2% male, mean age 70 ± 11). The main comorbidities observed included arterial hypertension, hyperlipidemia, and obesity, with metformin and statins being the treatments most frequently prescribed. MACE development was associated with multivessel (Hazard Ratio (HR) = 2.49) and single coronary vessel disease (HR = 1.71), transient ischemic attack (HR = 2.01), heart failure (HR = 1.32), insulin treatment (HR = 1.40), and percutaneous coronary intervention (PCI) (HR = 2.27), whilst statins (HR = 0.73) were associated with a lower risk of MACE occurrence. In conclusion, we found six risk factors associated with the development of MACE which were related with cardiovascular diseases and T2DM severity, and treatment with statins was identified as a protective factor for new MACE in this study.